PBX3 is a putative biomarker of aggressive prostate cancer

    loading  Checking for direct PDF access through Ovid


There is a great need to identify new and better prognostic and predictive biomarkers to stratify prostate cancer patients for optimal treatment. The aims of this study were to characterize the expression profile of pre-B cell leukemia homeobox (PBX) transcription factors in prostate cancer with an emphasis on investigating whether PBX3 harbours any prognostic value. The expression profile of PBX3 and PBX1 in prostate tissue was determined by immunohistochemical and immunoblot analysis. Furthermore, the expression of PBX3 transcript variants was analyzed by RT-PCR, NanoString Technologies®, and by analyzing RNA sequence data. The potential of PBX3 to predict prognosis, either at mRNA or protein level, was studied in four independent cohorts. PBX3 was mainly expressed in the nucleus of normal prostate basal cells, while it showed cytosolic expression in prostatic intraepithelial neoplasia and cancer cells. We detected four PBX3 transcript variants in prostate tissue. Competing risk regression analysis revealed that high PBX3 expression was associated with slower progression to castration resistant prostate cancer (sub-hazard ratio (SHR) 0.18, 95% CI: 0.081–0.42, p values < 0.001). PBX3 expression had a high predictive accuracy (area under the curve (AUC) = 0.82) when combined with Gleason score and age. Patients undergoing radical prostatectomy, with high levels of PBX3 mRNA, had improved prostate cancer specific survival compared to patients expressing low levels (SHR 0.21, 95% CI: 0.46–0.93, p values < 0.001, and AUC = 0.75). Our findings strongly indicate that PBX3 has potential as a biomarker, both as part of a larger gene panel and as an immunohistochemical marker, for aggressive prostate cancer.

What's new?

Pioneer transcription factors bind directly to condensed chromatin and thereby facilitate cellular reprogramming. Hence, certain pioneer factors are implicated in cancer, including members of the pre-B cell leukemia homeobox (PBX) family. Little is known, however, about their role in cancer. In this study, elevated expression of PBX3 was associated with a reduced rate of progression to castration-resistant prostate cancer. Unique patterns of PBX3 expression were identified in normal versus cancerous prostate cells, and multiple PBX3 transcript variants were identified in prostate tissue. PBX3 is a potential biomarker for the identification of patients at increased risk of castration-resistant prostate cancer.

Related Topics

    loading  Loading Related Articles